• 雙方的首要合作是在中國加速開發用於治療實體腫瘤的2seventy的MAGE-A4項目

中國上海和美國馬薩諸塞州劍橋市2022年10月27日 /美通社/ -- 藥明巨諾（港交所代碼：2126），一家獨立的、專注於開發、生產及商業化細胞免疫治療產品的創新型生物科技公司，與2seventy bio（納斯達克代碼：TSVT），一家領先的免疫腫瘤細胞治療公司，今天宣佈達成戰略合作。雙方將建立細胞治療的轉化及臨床開發平台，在中國內地、香港及澳門地區加速T細胞免疫治療產品的開發。

雙方的首要合作將圍繞2seventy的MAGE-A4 TCR項目，該項目用於治療實體腫瘤，由2seventy與再生元（Regeneron）合作開發。MAGE-A4是癌-睪丸抗原MAGE家族的一員，這類抗原在多種實體腫瘤中均有表達。該項目旨在開發T細胞受體（TCR）療法，用於治療MAGE-A4陽性的實體腫瘤。

藥明巨諾首席醫學官Mark J. Gilbert博士表示：「我們很高興與2seventy bio攜手，在中國共同開發MAGE-A4 TCR項目及其他潛在的產品。2seventy bio是一家業界一流的細胞治療公司，擁有先進的技術及經驗豐富的團隊。此次戰略合作將進一步發揮我們包括轉化研究及臨床開發在內的、世界一流的綜合能力，我們期待加速開發更多具有突破性治療價值的細胞免疫治療產品，服務更多中國乃至全球的癌症患者。」

2seventy bio首席醫學官Steve Bernstein表示：「此次合作對於患者的真正價值，在於我們增強了快速測試、學習並推進我們創新細胞治療項目的能力。藥明巨諾對於中國患者未被滿足的治療需求、中國的註冊事務流程、以及臨床開發路徑具有深入的洞察。借助此次合作機會，我們將彼此的獨特優勢經驗相互結合，建立差異化的平台，從而實現我們的目標，即讓創新治療更快地惠及患者。」

根據協議條款，2seventy將授權藥明巨諾在中國內地、香港及澳門地區開展MAGE-A4細胞治療項目的權利，藥明巨諾將負責其在中國的開發、生產及商業化，2seventy有權獲得里程碑付款及基於產品收入的特許權使用費。此外，2seventy可將基於該合作項目而獲得的早期臨床數據用於在其他地區開發該產品。此次交易的完成尚待取得藥明巨諾股東的批准，並滿足其他慣例成交條件。

關於MAGE-A4項目

MAGE-A4是癌-睪丸抗原MAGE家族的一員，這類抗原在多種實體腫瘤中均有表達。我們構造了我們在與MediGene的合作中發現的一種高效的TCR，該TCR可識別HLA呈遞的MAGE-A4多肽，並憑借我們CTBR12 TGF-beta「翻轉」受體技術進一步增強這些T細胞的效力，將TGF-beta免疫抑制效應轉化為T細胞的激活信號。再生元（Regeneron）和2seventy bio於2018年圍繞此項目達成合作，目前雙方正在合作開發。

關於藥明巨諾

藥明巨諾（港交所代碼：2126）是一家獨立的、創新型的生物科技公司，專注於開發、生產及商業化細胞免疫治療產品，並致力於以創新為先導，成為細胞免疫治療引領者。創建於2016年，藥明巨諾已成功打造了國際領先的細胞免疫治療的綜合性產品開發平台，以及涵蓋血液及實體腫瘤的細胞免疫治療產品管線。藥明巨諾致力於以突破性、高品質的細胞免疫治療產品給中國乃至全球患者帶來治癒的希望，並引領中國細胞免疫治療產業的健康規範發展。欲瞭解更多詳情，請訪問：www.jwtherapeutics.com。

關於2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape.

With a deep understanding of the human body』s immune response to tumor cells and how to translate cell therapies into practice, we』re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to 「think」 smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our 「why」 and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: Twitter and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

藥明巨諾前瞻性聲明

本發佈所包含的前瞻性聲明是基於管理層現有的期望和信心，會存在一定的不確定性或風險從而導致實際結果在實質上與所描述的有所區別。顯著的風險和不確定性，可能包括了以下涉及的內容，以及在公司提交給香港交易所（HKEX）的報告中予以更為全面的描述。除非另有註明，公司提供截至發佈日期當日的信息，並且明確無義務更新相關事項及其所含內容或提供任何解釋。具體內容，詳見公司官網：www.jwtherapeutics.com/cn/forward-looking-statements/。

Cautionary Note Regarding Forward-Looking Statements of 2seventy bio

This release contains 「forward-looking statements」 within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, manufacture or sale of our product candidates, including the results and expected timing of ongoing and planned clinical trials for our product candidates in China and the speed with which we can bring those candidates into clinical trials; statements about the efficacy and perceived therapeutic benefits of our product candidates and the potential indications, market opportunities and demand therefor; statements about the strategic plans for 2seventy bio and potential corporate development opportunities; statements regarding the company』s financial condition, and other future financial results; and statements about our ability to execute our strategic priorities. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation; the risk that our plans with respect to the preclinical and clinical development and regulatory approval of our product candidates may not be successfully achieved on the planned timeline, or at all. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 「Risk Factors」 in our annual report on Form 10-K for the year ended December 31, 2021, as supplemented and/or modified by our most recent Quarterly Report on Form 10-Q and any other filings that we have made or will make with the Securities and Exchange Commission in the future. All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.

藥明巨諾

投資者問詢：
IR_JW@jwtherapeutics.com

媒體問詢：
Communications@jwtherapeutics.com

2seventy bio

投資者問詢：
Elizabeth Pingpank, +1 860-463-0469
elizabeth.pingpank@2seventybio.com

媒體問詢：
Morgan Adams, +1 774-313-9852
morgan.adams@2seventybio.com